Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation
暂无分享,去创建一个
[1] C McRae,et al. Myocardial infarction. , 2019, Australian family physician.
[2] I. T. Ten Berge,et al. Treatment with everolimus is associated with a procoagulant state. , 2013, Thrombosis research.
[3] R. Porte,et al. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[4] D. Brieger,et al. Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. , 2013, Thrombosis research.
[5] R. Porte,et al. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.
[6] F. Rosendaal,et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. , 2010, Blood.
[7] R. Porte,et al. Intact thrombomodulin‐mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulin‐mediated regulation of coagulation , 2010, Journal of thrombosis and haemostasis : JTH.
[8] J. Rosing,et al. Thrombin generation‐based assays to measure the activity of the TFPI–protein S pathway in plasma from normal and protein S‐deficient individuals , 2010, Journal of thrombosis and haemostasis : JTH.
[9] R. Porte,et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. , 2010, Journal of hepatology.
[10] M. Senzolo,et al. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[11] Johnny C. Hong,et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. , 2009, Journal of the American College of Surgeons.
[12] R. Porte,et al. Development of a Severe von Willebrand Factor/ADAMTS13 Dysbalance During Orthotopic Liver Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] E. Horváth-Puhó,et al. Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study , 2009, The American Journal of Gastroenterology.
[14] M. J. Fabiá,et al. [Venous thromboembolism and liver cirrhosis]. , 2008, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[15] F. Rosendaal,et al. Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis , 2008, PLoS medicine.
[16] N. Chalasani,et al. Deep Vein Thrombosis and Pulmonary Embolism in Cirrhosis Patients , 2008, Digestive Diseases and Sciences.
[17] R. van Oerle,et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population , 2007, Journal of thrombosis and haemostasis : JTH.
[18] W. Sluiter,et al. Vascular events after liver transplantation: a long‐term follow‐up study , 2007, Transplant international : official journal of the European Society for Organ Transplantation.
[19] M. Vivarelli,et al. Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] S. Caldwell,et al. Coagulopathy Does Not Fully Protect Hospitalized Cirrhosis Patients from Peripheral Venous Thromboembolism , 2006, The American Journal of Gastroenterology.
[21] Yoshihiro Kokubo,et al. FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.
[22] A. Tripodi,et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests , 2005, Hepatology.
[23] F. Rosendaal,et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. , 2004, Blood.
[24] A. Folsom,et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). , 2002, The American journal of medicine.
[25] M. Carrier,et al. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[26] P. D. de Groot,et al. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation , 2002, Hepatology.
[27] M. Picard,et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. , 2001, Transplantation.
[28] T. Rabelink,et al. Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation. , 2001, The Netherlands journal of medicine.
[29] J. McMurray,et al. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. , 2000, Kidney international.
[30] A. Folsom,et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.
[31] T. Nilsson,et al. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction , 1998, Heart.
[32] B. Meiser,et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. , 1998, Transplantation proceedings.
[33] D. Dunn,et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. , 1998, Transplantation.
[34] A. Haeberli,et al. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. , 1996, The Journal of laboratory and clinical medicine.
[35] J. Whitworth,et al. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[36] D. Di Landro,et al. Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. , 1995, Transplantation.
[37] H. Büller,et al. IMPAIRED FIBRINOLYSIS IN CYCLOSPORINE‐TREATED RENAL TRANSPLANT PATIENTS ANALYSIS OF THE DEFECT AND BENEFICIAL EFFECT OF FISH‐OIL , 1992, Transplantation.
[38] H. Ohlin,et al. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. , 1987, Thrombosis research.
[39] P. Morris,et al. Deep venous thrombosis after renal transplantation. , 1987, Transplantation proceedings.
[40] M. Blombäck,et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.
[41] I. Martinelli. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. , 2005, Seminars in hematology.
[42] A. Irish,et al. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[43] The 12th Report of the Human Renal Transplant Registry. Prepared by the Advisory Committee to the Renal Transplant Registry. , 1975, JAMA.